STAAR Surgical (STAA) Competitors

STAAR Surgical (NASDAQ:STAA) and Haemonetics (NYSE:HAE) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations, community ranking and media sentiment.

Does the media favor STAA or HAE?

In the previous week, STAAR Surgical had 5 more articles in the media than Haemonetics. MarketBeat recorded 12 mentions for STAAR Surgical and 7 mentions for Haemonetics. STAAR Surgical's average media sentiment score of 1.22 beat Haemonetics' score of 0.07 indicating that STAAR Surgical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
STAAR Surgical	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Haemonetics	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community favor STAA or HAE?

Haemonetics received 107 more outperform votes than STAAR Surgical when rated by MarketBeat users. Likewise, 61.43% of users gave Haemonetics an outperform vote while only 55.28% of users gave STAAR Surgical an outperform vote.

Company	Underperform	Outperform
STAAR Surgical	Outperform Votes 288 55.28%	Underperform Votes 233 44.72%
Haemonetics	Outperform Votes 395 61.43%	Underperform Votes 248 38.57%

Do analysts rate STAA or HAE?

STAAR Surgical currently has a consensus target price of $42.83, suggesting a potential upside of 92.16%. Haemonetics has a consensus target price of $108.78, suggesting a potential upside of 47.74%. Given STAAR Surgical's higher possible upside, equities research analysts clearly believe STAAR Surgical is more favorable than Haemonetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
STAAR Surgical	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.33
Haemonetics	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.89

Is STAA or HAE more profitable?

Haemonetics has a net margin of 9.10% compared to STAAR Surgical's net margin of 6.38%. Haemonetics' return on equity of 22.67% beat STAAR Surgical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
STAAR Surgical	6.38%	6.77%	5.39%
Haemonetics	9.10%	22.67%	8.83%

Which has more risk and volatility, STAA or HAE?

STAAR Surgical has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500. Comparatively, Haemonetics has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500.

Which has preferable earnings & valuation, STAA or HAE?

Haemonetics has higher revenue and earnings than STAAR Surgical. Haemonetics is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
STAAR Surgical	$322.42M	3.41	$21.35M	$0.44	50.66
Haemonetics	$1.31B	2.82	$117.56M	$2.41	30.55

Do institutionals and insiders hold more shares of STAA or HAE?

96.7% of STAAR Surgical shares are held by institutional investors. Comparatively, 99.7% of Haemonetics shares are held by institutional investors. 1.0% of STAAR Surgical shares are held by company insiders. Comparatively, 1.8% of Haemonetics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Haemonetics beats STAAR Surgical on 13 of the 19 factors compared between the two stocks.